Dongyang Sun Pharmaceutical will win 2.5 billion anti-ED drug-Sildenafil

Recently, the official website of NMPA shows that Dongyang Pharmaceutical has entered the administrative examination and approval stage with the imitation of sildenafil citrate tablets reported for production in category 4, and is expected to be approved for listing in the near future
.
Sildenafil is a mainstream anti-ED drug.
In 2020, the terminal sales of physical pharmacies in Chinese cities will exceed 2.
5 billion yuan, a year-on-year increase of 8.
57%
.
Sildenafil Citrate is a type 5 phosphodiesterase (PDE-5) selective inhibitor developed by Pfizer for the treatment of erectile dysfunction (ED)
.
PDE-5 inhibitor drugs are the main products in the anti-ED market.
Sildenafil, tadalafil, and vardenafil are the three main PDE-5 inhibitors in the global market
.
According to data from Meinenet, the domestic market of Sildenafil has continued to expand in recent years.
In 2020, the terminal sales of physical pharmacies in Chinese cities will exceed 2.
5 billion yuan, a year-on-year increase of 8.
57%
.
With the efforts of local companies, the original research manufacturer Pfizer's market share has continued to decline, from 52.
60% in 2017 to 44.
08% in 2020
.
The sales of sildenafil at physical pharmacies in cities in China (unit: 10,000 yuan) Source: Mynet.
com Competitive pattern at physical pharmacies in cities in China.
It is worth mentioning that in the physical pharmacy market, sildenafil is also the leading product of urinary system drugs
.
Among the urinary system drugs in the terminal chemical drugs of physical pharmacies in Chinese cities in 2020, the TOP5 products are Sildenafil Citrate Tablets, Tadalafil Tablets, Finasteride Tablets, Tamsulosin Hydrochloride Sustained Release Capsules, and Tansulosin Hydrochloride Luoxin sustained-release tablets, the total market share is as high as 93.
5%
.
Sildenafil citrate tablets are far ahead of the second-ranked tadalafil tablets with sales of more than 2.
5 billion yuan
.
TOP5 urinary system drug products for terminal chemical drugs in physical pharmacies in Chinese cities in 2020.
Source: Meinenet.
com.
The terminal competition pattern of physical pharmacies in Chinese cities.
Sildenafil citrate tablets have been included in the third batch of centralized procurement, and 9 companies have been reviewed, including Qilu Pharmaceutical, Baiyunshan, Yangtze River Pharmaceutical, Guangshengtang, China Resources SECCO, Yabang Epson, etc.

.
In addition, 4 types of imitation applications of sildenafil citrate tablets from 6 companies are under review
.
The registration status of this product of Dongyang Sunshine Pharmaceuticals has been changed to "under approval".
If it is successfully approved, it will be deemed as over-evaluated
.
Data source: Meinenet database, NMPA Note: Meinenet China's urban physical pharmacy terminal competition pattern database is an enlarged version of continuous monitoring of the entire category covering 297 physical pharmacies in cities and above cities across the country (excluding county and rural physical pharmacies) Database of physical pharmacies in the city
.
The above sales are calculated based on the average retail price of the product at the terminal
.